Are there any concerns with live vaccine innoculation and patients who are on denosumab?

This is a complicated question because while denosumab is a biologic therapeutic that has immunomodulatory effects on innate and adaptive immunity its association with serious infections complications appears modest. An increased rate of background infections and some increase in serious infections ...

I agree completely with the response. In treating hundreds of patients with Denosumab, we have not found any problem. Quite a different attitude than with the use of biologics in inflammatory disorders.